Sodium–glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients
Open Access
- 20 June 2020
- journal article
- review article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 12 (1) , 6-20
Abstract
Recent major clinical trials of the use of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes have shown that they reduce three‐point major adverse cardiovascular events, cardiovascular death, hospitalization for heart failure (HF) and a composite renal outcome. These beneficial effects of SGLT2 inhibitors are also evident in type 2 diabetes patients with a previous history of atherosclerotic cardiovascular disease or advanced renal disease. HF is a major determinant of the prognosis of diabetes patients. Although HF with low ejection fraction can be effectively treated with antihypertensive drugs, these treatments do not reduce mortality in HF patients with preserved ejection fraction (HFpEF). HFpEF is clinically characterized by left ventricular diastolic dysfunction, perivascular fibrosis and stiffness of cardiomyocytes, defined as “cardiomyopathy”. Therefore, HFpEF is considered to be an entirely separate entity to HF with low ejection fraction. Recent studies have suggested that HFpEF might be treatable using SGLT2 inhibitors, which ameliorate visceral adiposity, insulin resistance, hyperglycemia, hyperlipidemia, volume overload, hypertension and cardiac inflammation. In the final part of the present review, we discuss the biochemical and molecular mechanisms of the effects of SGLT2 inhibitors in type 2 diabetes patients with HFpEF. These involve amelioration of the low nitric oxide production and oxidative stress, a reduction in cardiac inflammatory cytokine signaling, inhibition of Ca2+ overload, and an improvement in cardiac energy metabolism as a result of ketone body production. Investigations of the beneficial effects of SGLT2 inhibitors on cardiorenal outcomes, including hospitalization for HF, are now being carried out in preclinical and clinical studies.Keywords
This publication has 101 references indexed in Scilit:
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic miceEuropean Journal of Pharmacology, 2013
- Oxidative stress and myocardial injury in the diabetic heartThe Journal of Pathology, 2012
- Lipid Metabolism and Toxicity in the HeartCell Metabolism, 2012
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on MetforminThe Journal of Clinical Endocrinology & Metabolism, 2012
- Biology of Human Sodium Glucose TransportersPhysiological Reviews, 2011
- Renal glucose reabsorption inhibitors to treat diabetesTrends in Pharmacological Sciences, 2011
- Epidemiology and Clinical Course of Heart Failure with Preserved Ejection FractionEuropean Journal of Heart Failure, 2011
- Inflammatory cytokines in vascular dysfunction and vascular diseaseBiochemical Pharmacology, 2009
- Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesityCell and tissue research, 2008
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999